Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Health Policy and Economics
•
Biologic Therapy/Immunobiology
•
Rheumatology
•
General Rheumatology
How do you structure letters of appeal/letters of medical necessity for therapeutics that are denied by insurance companies?
Related Questions
Can joint replacement surgery be performed in someone with active Paget’s disease elsewhere?
What is your approach to tapering chronic steroids in patients who are at high risk of HPA suppression?
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?
How do you approach management of adult patients with CVID and sarcoid-like syndrome?
How would you approach treatment of active inflammatory arthritis in a patient with MCTD (+RNP/+Chromatin) and stable ILD who has failed MMF, azathioprine and methotrexate?
When would you consider using G-CSF in patients with rheumatic disease who have received cyclophosphamide?
What is your approach to the management of isolated total hip osteoporosis in a post menopausal woman without fracture history and low FRAX risk (based on their femoral neck osteopenic t score)?
What baseline and ongoing testing do you recommend for patients with PMR who are going to be on a prolonged steroid taper?
In patients with rheumatologic disease on DMARDs and/or biologics how do you counsel them regarding blood donation?
For how long do you recommend treatment for latent tuberculosis prior to initiation of anti-TNF therapy?